Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 2, 2012, Pages 286-292

  Fang, Fang ^a   Chen, Xiaochun ^b   Huang, Tianwen ^b   Lue, Lih Fen ^c   Luddy, John S ^a   Yan, Shirley ShiDu ^a,d  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

AD mouse model; Gamma secretase; Neuroprotection; Rg1

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA SECRETASE; GINSENOSIDE RG 1; GLUTAMIC ACID;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; LEARNING; MALE; MEMORY; MOUSE; NERVE CELL CULTURE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPATIAL LEARNING;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CEREBELLUM; COGNITION; COGNITION DISORDERS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; GINSENOSIDES; GLUTAMIC ACID; HUMANS; LEARNING; MEMORY; MICE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION;

MUS; PANAX GINSENG;

EID: 83455245428     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.004     Document Type: Article

References (50)

1. Attele A.S., Wu J.A., Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58:1685-1693.
2. Cheng Y., Shen L.H., Zhang J.T. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol. Sin. 2005, 26:143-149.
3. Fu L.M., Li J.T. A systematic review of single Chinese herbs for Alzheimer's disease treatment. Evid. Based Complement. Alternat. Med. 2009, 15:133-145.
4. Zhang JT C.D.-H., Chen C.-f., Liu G.Z. The chemistry, metabolism and biological activities of ginseng 2006, Chemical Industry Press, Beijing.
5. Hu S.Q., Yu H.M., Liu T.S., Yang D.J., Chen X.Z., He C.J. Neuroprotective effects of water extracts of American Ginseng on SH-SY5Y cells apoptosis induced by Abeta25-35. Zhong Yao Cai 2008, 31:1373-1377.
6. Chang Y., Wang S.J. Ginsenoside Rg1 and Rb1 enhance glutamate exocytosis from rat cortical nerve terminals by affecting vesicle mobilization through the activation of protein kinase C. Eur. J. Pharmacol. 2008, 590:74-79.
7. 2+ channels. Eur. J. Pharmacol. 2008, 586:90-99.
8. Xu L., Chen W.F., Wong M.S. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br. J. Pharmacol. 2009, 158:738-748.
9. Wei C., Jia J., Liang P., Guan Y. Ginsenoside Rg1 attenuates beta-amyloid-induced apoptosis in mutant PS1 M146L cells. Neurosci. Lett. 2008, 443:145-149.
10. Ji Z.N., Dong T.T., Ye W.C., Choi R.C., Lo C.K., Tsim K.W. Ginsenoside Re attenuate beta-amyloid and serum-free induced neurotoxicity in PC12 cells. J. Ethnopharmacol. 2006, 107:48-52.
11. Choi R.C., Zhu J.T., Leung K.W., Chu G.K., Xie H.Q., Chen V.P., Zheng K.Y., Lau D.T., Dong T.T., Chow P.C., Han Y.F., Wang Z.T., Tsim K.W. A flavonol glycoside, isolated from roots of panax notoginseng, reduces amyloid-beta-induced neurotoxicity in cultured neurons: signaling transduction and drug development for Alzheimer's disease. J. Alzheimers Dis. 2010, 19:795-811.
12. Chen F., Eckman E.A., Eckman C.B. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J. 2006, 20:1269-1271.
13. Shi Y.Q., Huang T.W., Chen L.M., Pan X.D., Zhang J., Zhu Y.G., Chen X.C. Ginsenoside Rg1 attenuates amyloid-beta ontent, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J. Alzheimers Dis. 2010, 19:977-989.
14. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399:A23-A31.
15. Vassar R., Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron 2000, 27:419-422.
16. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
17. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2040-2041.
18. Arancio O., Zhang H.P., Chen X., Lin C., Trinchese F., Puzzo D., Liu S., Hegde A., Yan S.F., Stern A., Luddy J.S., Lue L.F., Walker D.G., Roher A., Buttini M., Mucke L., Li W., Schmidt A.M., Kindy M., Hyslop P.A., Stern D.M., Du Yan S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004, 23:4096-4105.
19. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
20. Takuma K., Yao J., Huang J., Xu H., Chen X., Luddy J., Trillat A.C., Stern D.M., Arancio O., Yan S.S. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J. 2005, 19:597-598.
21. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14:1097-1105.
22. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18670-18675.
23. Du H., Guo L., Zhang W., Rydzewska M., Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol. Aging 2011, 32:398-406.
24. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3228-3233.
25. Du H., Guo L., Zhang W., Rydzewska M., Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol. Aging 2011, 32:398-406.
26. Xu X., Yang D., Wyss-Coray T., Yan J., Gan L., Sun Y., Mucke L. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7547-7552.
27. Fang F., Lue L.F., Yan S., Xu H., Luddy J.S., Chen D., Walker D.G., Stern D.M., Yan S., Schmidt A.M., Chen J.X., Yan S.S. RAGE-dependent signaling in microglia contributes to neuroinflammation, A{beta} accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 2010, 24:1043-1055.
28. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
29. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13217-13221.
30. Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology 1998, 51:S18-S29. (discussion S65-17).
31. Masliah E., Terry R.D., DeTeresa R.M., Hansen L.A. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 1989, 103:234-239.
32. Yamamoto-Sasaki M., Ozawa H., Saito T., Rosler M., Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res. 1999, 824:300-303.
33. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 2004, 114:1624-1634.
34. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M., Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126:775-788.
35. Arancio O., Chao M.V. Neurotrophins, synaptic plasticity and dementia. Curr. Opin. Neurobiol. 2007, 17:325-330.
36. Duffy S.N., Nguyen P.V. Postsynaptic application of a peptide inhibitor of cAMP-dependent protein kinase blocks expression of long-lasting synaptic potentiation in hippocampal neurons. J. Neurosci. 2003, 23:1142-1150.
37. Nguyen P.V., Woo N.H. Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. Prog. Neurobiol. 2003, 71:401-437.
38. Dineley K.T., Westerman M., Bui D., Bell K., Ashe K.H., Sweatt J.D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 2001, 21:4125-4133.
39. Bach M.E., Barad M., Son H., Zhuo M., Lu Y.F., Shih R., Mansuy I., Hawkins R.D., Kandel E.R. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5280-5285.
40. Silva A.J., Kogan J.H., Frankland P.W., Kida S. CREB and memory. Annu. Rev. Neurosci. 1998, 21:127-148.
41. Zhao H., Li Q., Zhang Z., Pei X., Wang J., Li Y. Long-term ginsenoside consumption prevents memory loss in aged SAMP8 mice by decreasing oxidative stress and up-regulating the plasticity-related proteins in hippocampus. Brain Res. 2009, 1256:111-122.
42. Lahiri D.K., Kotwal G.J., Farlow M.R., Sima A., Kupsky W., Sarkar F.H., Sambamurti K. The role of the carboxyl-terminal fragments of amyloid precursor protein in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2002, 973:334-339.
43. Elvang A.B., Volbracht C., Pedersen L.O., Jensen K.G., Karlsson J.J., Larsen S.A., Mork A., Stensbol T.B., Bastlund J.F. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J. Neurochem. 2009, 110:1377-1387.
44. Wolfe M.S. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008, 5:391-398.
45. Barco A., Pittenger C., Kandel E.R. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin. Ther. Targets 2003, 7:101-114.
46. Matsuzaki K., Yamakuni T., Hashimoto M., Haque A.M., Shido O., Mimaki Y., Sashida Y., Ohizumi Y. Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci. Lett. 2006, 400:230-234.
47. Liang Z., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J. Neurochem. 2007, 103:2462-2470.
48. Puzzo D., Vitolo O., Trinchese F., Jacob J.P., Palmeri A., Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 2005, 25:6887-6897.
49. Smith D.L., Pozueta J., Gong B., Arancio O., Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16877-16882.
50. Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., Zhang H., Feng Y., Palmeri A., Landry D.W., Arancio O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J. Neurosci. 2009, 29:8075-8086.